UBS AM’s Elevance Health ELV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $737M | Buy |
2,518,615
+170,844
| +7% | +$56.1M | 0.15% | 124 |
|
|
2025
Q4 | $823M | Sell |
2,347,771
-38,288
| -2% | -$12.9M | 0.17% | 104 |
|
|
2025
Q3 | $771M | Sell |
2,386,059
-593,262
| -20% | -$185M | 0.17% | 110 |
|
|
2025
Q2 | $1.16B | Buy |
2,979,321
+303,118
| +11% | +$122M | 0.23% | 91 |
|
|
2025
Q1 | $1.16B | Buy |
2,676,203
+324,040
| +14% | +$130M | 0.3% | 67 |
|
|
2024
Q4 | $868M | Buy |
2,352,163
+199,550
| +9% | +$83.5M | 0.2% | 87 |
|
|
2024
Q3 | $1.12B | Buy |
2,152,613
+31,740
| +1% | +$17M | 0.29% | 65 |
|
|
2024
Q2 | $1.15B | Buy |
2,120,873
+451,811
| +27% | +$239M | 0.33% | 56 |
|
|
2024
Q1 | $865M | Sell |
1,669,062
-38,282
| -2% | -$19M | 0.31% | 61 |
|
|
2023
Q4 | $805M | Buy |
1,707,344
+21,589
| +1% | +$9.98M | 0.32% | 56 |
|
|
2023
Q3 | $734M | Buy |
1,685,755
+87,358
| +5% | +$39.6M | 0.33% | 56 |
|
|
2023
Q2 | $735M | Hold |
1,598,397
| – | – | 0.36% | 54 |
|
|
2023
Q1 | $735M | Sell |
1,598,397
-29,541
| -2% | -$14.1M | 0.36% | 54 |
|
|
2022
Q4 | $835M | Buy |
1,627,938
+39,803
| +3% | +$20.2M | 0.44% | 40 |
|
|
2022
Q3 | $721M | Sell |
1,588,135
-81,418
| -5% | -$39M | 0.4% | 43 |
|
|
2022
Q2 | $806M | Buy |
1,669,553
+569,965
| +52% | +$282M | 0.42% | 42 |
|
|
2022
Q1 | $540M | Sell |
1,099,588
-28,198
| -3% | -$12.9M | 0.23% | 85 |
|
|
2021
Q4 | $523M | Sell |
1,127,786
-604,898
| -35% | -$254M | 0.2% | 109 |
|
|
2021
Q3 | $646M | Buy |
1,732,684
+588,390
| +51% | +$224M | 0.27% | 73 |
|
|
2021
Q2 | $437M | Sell |
1,144,294
-105,260
| -8% | -$40.2M | 0.19% | 116 |
|
|
2021
Q1 | $449M | Sell |
1,249,554
-437,957
| -26% | -$141M | 0.2% | 104 |
|
|
2020
Q4 | $542M | Sell |
1,687,511
-57,969
| -3% | -$17.8M | 0.25% | 79 |
|
|
2020
Q3 | $469M | Buy |
1,745,480
+64,685
| +4% | +$17.4M | 0.25% | 79 |
|
|
2020
Q2 | $442M | Buy |
1,680,795
+38,164
| +2% | +$10.2M | 0.27% | 75 |
|
|
2020
Q1 | $373M | Sell |
1,642,631
-179,187
| -10% | -$48.8M | 0.27% | 73 |
|
|
2019
Q4 | $550M | Sell |
1,821,818
-262,570
| -13% | -$72.3M | 0.34% | 57 |
|
|
2019
Q3 | $500M | Buy |
2,084,388
+208,760
| +11% | +$57.2M | 0.34% | 56 |
|
|
2019
Q2 | $529M | Sell |
1,875,628
-113,008
| -6% | -$30.9M | 0.38% | 51 |
|
|
2019
Q1 | $571M | Buy |
1,988,636
+42,586
| +2% | +$12.3M | 0.42% | 44 |
|
|
2018
Q4 | $511M | Sell |
1,946,050
-45,609
| -2% | -$12.5M | 0.44% | 42 |
|
|
2018
Q3 | $546M | Sell |
1,991,659
-169,260
| -8% | -$43.9M | 0.41% | 44 |
|
|
2018
Q2 | $514M | Buy |
2,160,919
+305,636
| +16% | +$70.8M | 0.39% | 43 |
|
|
2018
Q1 | $408M | Sell |
1,855,283
-75,887
| -4% | -$17.8M | 0.32% | 64 |
|
|
2017
Q4 | $435M | Buy |
1,931,170
+200,330
| +12% | +$42.7M | 0.37% | 53 |
|
|
2017
Q3 | $329M | Buy |
1,730,840
+147,079
| +9% | +$28M | 0.3% | 66 |
|
|
2017
Q2 | $298M | Buy |
1,583,761
+706,775
| +81% | +$127M | 0.29% | 72 |
|
|
2017
Q1 | $145M | Buy |
876,986
+68,942
| +9% | +$11M | 0.15% | 156 |
|
|
2016
Q4 | $116M | Sell |
808,044
-95,170
| -11% | -$12.7M | 0.13% | 177 |
|
|
2016
Q3 | $113M | Buy |
903,214
+42,771
| +5% | +$5.52M | 0.12% | 184 |
|
|
2016
Q2 | $113M | Buy |
860,443
+1,327
| +0.2% | +$182K | 0.13% | 180 |
|
|
2016
Q1 | $119M | Sell |
859,116
-92,170
| -10% | -$12.3M | 0.14% | 162 |
|
|
2015
Q4 | $133M | Sell |
951,286
-698,925
| -42% | -$96.3M | 0.15% | 159 |
|
|
2015
Q3 | $231M | Sell |
1,650,211
-110,480
| -6% | -$16.6M | 0.25% | 81 |
|
|
2015
Q2 | $289M | Buy |
1,760,691
+26,320
| +2% | +$4.21M | 0.28% | 81 |
|
|
2015
Q1 | $268M | Buy |
1,734,371
+256,903
| +17% | +$36.6M | 0.26% | 87 |
|
|
2014
Q4 | $186M | Buy |
1,477,468
+77,146
| +6% | +$9.53M | 0.18% | 132 |
|
|
2014
Q3 | $168M | Buy |
1,400,322
+49,143
| +4% | +$5.64M | 0.17% | 139 |
|
|
2014
Q2 | $145M | Sell |
1,351,179
-30,233
| -2% | -$3.12M | 0.15% | 158 |
|
|
2014
Q1 | $138M | Buy |
1,381,412
+131,788
| +11% | +$11.9M | 0.15% | 165 |
|
|
2013
Q4 | $115M | Buy |
1,249,624
+253
| +0% | +$22.5K | 0.13% | 185 |
|
|
2013
Q3 | $104M | Buy |
1,249,371
+8,437
| +0.7% | +$723K | 0.13% | 186 |
|
|
2013
Q2 | $102M | Buy |
+1,240,934
| New | +$92.9M | 0.13% | 182 |
|
Other funds holding ELV
VCM
VPM
UBS AM's ELV Position: Q1 2026 in Review
UBS AM increased its Elevance Health (ELV) stake by 7.3% in Q1 2026, buying an estimated $56.1M and bringing the position to 2,518,615 shares worth $737M. The position accounts for 0.15% of the portfolio, ranked #124.
UBS AM first reported a position in ELV in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.16B in Q1 2025. 1,462 funds tracked by Wall St. Rank hold ELV as of Q1 2026.
- UBS AM held 2,518,615 shares of Elevance Health worth $737M as of Q1 2026.
- UBS AM bought 170,844 Elevance Health shares in Q1 2026, an estimated $56.1M.
- Elevance Health made up 0.15% of UBS AM's portfolio in Q1 2026, its #124 holding.
- UBS AM first reported a position in Elevance Health in Q2 2013 and has held it in 52 quarters since.
- UBS AM's Elevance Health position peaked at $1.16B in Q1 2025.
- 1,462 funds tracked by Wall St. Rank held Elevance Health as of Q1 2026.
Based on UBS AM's 13F filing for Q1 2026, filed 13 May 2026.